Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Viking Therapeutics (VKTX) currently carries a favorable average brokerage recommendation (ABR) of 1.32, nearing a 'Strong Buy' based on 19 firms. However, the article advises caution against relying solely on ABRs due to inherent positive bias from brokerage firms. Notably, VKTX's Zacks Consensus Estimate for current year EPS has declined 2.4% over the past month to -$2.48, leading to a Zacks Rank #4 (Sell), suggesting a potentially negative outlook despite the optimistic sell-side ratings.

Analysis

Viking Therapeutics (VKTX) presents a significant divergence between bullish sell-side sentiment and deteriorating near-term earnings fundamentals. The company holds a strong Average Brokerage Recommendation (ABR) of 1.32, with 16 of 19 covering firms (84.2%) assigning a 'Strong Buy' rating. However, this optimism is contradicted by underlying estimate revisions. The Zacks Consensus Estimate for VKTX's current-year earnings per share has declined by 2.4% over the last month to -$2.48. This negative revision, reflecting growing analyst pessimism on earnings, is the primary driver for the stock's Zacks Rank #4 (Sell), indicating a potential for near-term price depreciation and challenging the validity of the consensus 'Buy' recommendation.

Key Decisions for Investors

• Investors should view the overwhelmingly positive sell-side consensus on Viking Therapeutics with caution, given the direct contradiction from negative earnings estimate revisions.
• The recent 2.4% downward revision in the current-year consensus EPS to -$2.48 should be considered a significant near-term risk factor, as such trends are often correlated with stock price underperformance.
• It is prudent to weigh the bearish signal from the Zacks Rank #4 (Sell), which is based on quantitative earnings data, against the more subjective and potentially biased 'Strong Buy' ratings from brokerage analysts before initiating or adding to a position.